Stage I-IIA non-bulky Hodgkin's lymphoma. Is further distinction based on prognostic factors useful? the Stanford experience

International Journal of Radiation Oncology Biology Physics

Volumn 81, Issue 5, 2011, Pages 1374-1379

  Advani, Ranjana H ^a   Hoppe, Richard T ^a   Maeda, Lauren S ^a   Baer, David M ^b   Mason, Joseph ^b   Rosenberg, Saul A ^a   Horning, Sandra J ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HODGKIN'S LYMPHOMA; MEDICAL CENTER; OVERALL SURVIVAL RATES; PROGNOSTIC FACTORS; PROGNOSTIC SIGNIFICANCE; RETROSPECTIVE ANALYSIS; RISK FACTORS; SEDIMENTATION RATES; STANFORD; STANFORD UNIVERSITY; STUDY GROUPS;

CHEMOTHERAPY; DISEASE CONTROL; DISEASES; ONCOLOGY; PATIENT MONITORING;

PATIENT TREATMENT;

ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGE FACTORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD SEDIMENTATION; CALIFORNIA; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HODGKIN DISEASE; HUMANS; LYMPH NODES; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY DOSAGE; RECURRENCE; RETROSPECTIVE STUDIES; TUMOR BURDEN; YOUNG ADULT;

EID: 81855206081     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2010.07.041     Document Type: Article

References (18)

1. M. Tubiana, A.M. Henry, and P. Carde Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC lymphoma group controlled clinical trials: 1964-1987 Blood 73 1989 47 56 (Pubitemid 19040952)
2. M. Sieber, A. Engert, and V. Diehl Treatment of Hodgkin's disease: Results and current concepts of the German Hodgkin's Lymphoma Study Group Ann Oncol 11 Suppl 1 2000 81 85
3. C. Gisselbrecht, N. Mounier, and M. Andre How to define intermediate stage in Hodgkin's lymphoma? Eur J Haematol Suppl 1 2005 11 14
4. D. Hasenclever, and V. Diehl A prognostic score for advanced Hodgkin's disease. International prognostic factors project on advanced Hodgkin's disease N Engl J Med 339 1998 1506 1514
5. J. Franklin, U. Paulus, D. Lieberz, K. Breuer, H. Tesch, and V. Diehl Is the international prognostic score for advanced stage Hodgkin's disease applicable to early stage patients? German Hodgkin Lymphoma Study Group Ann Oncol 11 2000 617 623 (Pubitemid 30431388)
6. V. Diehl, C. Brillant, and A. Engert Recent interim analysis of the HD11 trial of the GHSG: Intensification of chemotherapy and reduction of radiation dose in early unfavorable stage Hodgkin's lymphoma Blood 106 2005 816a
7. R.M. Meyer, M.K. Gospodarowicz, and J.M. Connors Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group J Clin Oncol 23 2005 4634 4642 (Pubitemid 46237440)
8. P. Borchmann, A. Engert, and A. Pluetschow Dose-intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by 2 cycles of ABVD and involved field radiotherapy (IF-RT) is superior to 4 cycles of ABVD and IFRT in patients with early unfavourable Hodgkin lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG) HD14 trial Blood 112 2008 367a
9. J. Raemaekers, H. Kluin-Nelemans, and I. Teodorovic The achievements of the EORTC Lymphoma Group. European Organisation for Research and Treatment of Cancer Eur J Cancer 38 Suppl 4 2002 S107 S113
10. S.J. Horning, R. Hoppe, and R. Advani Efficacy and late effects of Stanford V chemotherapy and radiotherapy in untreated Hodgkin's disease: Mature data in early and advanced stage patients Blood 104 2005 92a
11. S.J. Horning, R.T. Hoppe, S. Breslin, N.L. Bartlett, B.W. Brown, and S.A. Rosenberg Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: Mature results of a prospective clinical trial J Clin Oncol 20 2002 630 637 (Pubitemid 34111368)
12. P. Carbone, H. Kaplan, and K. Musshoff Report of the committee on the Hodgkin's disease staging Cancer Res 31 1971 1860
13. R.H. Advani, R.T. Hoppe, D.M. Baer, J. Mason, S.A. Rosenberg, and S.J. Horning Efficacy of Abbreviated Stanford V chemotherapy and involved field radiotherapy in early stage Hodgkin's disease: Mature results of the G4 trial Blood 114 2009 1670a
14. E.M.P. Kaplan Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
15. C. Ferme, M. Divine, and A. Vranovsky Four ABVD and involved-field radiotherapy in unfavorable supradiaphragmatic clinical stages (CS) I-II Hodgkin's lymphoma (HL): Preliminary results of the EORTC-GELA H9-U trial Blood 106 2005 813a
16. A. Gallamini, M. Hutchings, and L. Rigacci Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study J Clin Oncol 25 2007 3746 3752 (Pubitemid 47372616)
17. J. Radford Limited-stage disease: Optimal use of chemotherapy and radiation treatment Hematology Am Soc Hematol Educ Program 2008 321 325
18. C. Steidl, T. Lee, and S.P. Shah Tumor-associated macrophages and survival in classic Hodgkin's lymphoma N Engl J Med 362 2010 875 885